262 related articles for article (PubMed ID: 26674596)
1. Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment.
Tornyos A; Kehl D; D'Ascenzo F; Komócsi A
Prog Cardiovasc Dis; 2016; 58(5):483-94. PubMed ID: 26674596
[TBL] [Abstract][Full Text] [Related]
2. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
3. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
Hillis C; Crowther MA
Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
[TBL] [Abstract][Full Text] [Related]
4. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
[TBL] [Abstract][Full Text] [Related]
5. Direct Anticoagulants and Risk of Myocardial Infarction, a Multiple Treatment Network Meta-Analysis.
Kupó P; Szakács Z; Solymár M; Habon T; Czopf L; Hategan L; Csányi B; Borbás J; Tringer A; Varga G; Balaskó M; Sepp R; Hegyi P; Bálint A; Komócsi A
Angiology; 2020 Jan; 71(1):27-37. PubMed ID: 31533437
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
7. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
Prandoni P
Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
[TBL] [Abstract][Full Text] [Related]
8. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.
Zolfaghari S; Harenberg J; Froelich L; Wehling M; Weiss C
Semin Thromb Hemost; 2014 Feb; 40(1):121-8. PubMed ID: 24381153
[TBL] [Abstract][Full Text] [Related]
9. [New direct oral oral anticoagulants (DOACs) - indications of DOACs].
Darius H
Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 Mar; 49(3):182-90; quiz 191. PubMed ID: 24711238
[TBL] [Abstract][Full Text] [Related]
10. Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation.
Lee CJ; Gerds TA; Carlson N; Bonde AN; Gislason GH; Lamberts M; Olesen JB; Pallisgaard JL; Hansen ML; Torp-Pedersen C
J Am Coll Cardiol; 2018 Jul; 72(1):17-26. PubMed ID: 29957227
[TBL] [Abstract][Full Text] [Related]
11. Managing pulmonary embolism from presentation to extended treatment.
Cohen AT; Dobromirski M; Gurwith MM
Thromb Res; 2014 Feb; 133(2):139-48. PubMed ID: 24182642
[TBL] [Abstract][Full Text] [Related]
12. Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses.
Darwiche W; Bejan-Angoulvant T; Angoulvant D; Babuty D; Fauchier L
Thromb Haemost; 2016 Nov; 116(6):1150-1158. PubMed ID: 27580712
[TBL] [Abstract][Full Text] [Related]
13. Novel oral anticoagulants in acute coronary syndrome.
Costopoulos C; Niespialowska-Steuden M; Kukreja N; Gorog DA
Int J Cardiol; 2013 Sep; 167(6):2449-55. PubMed ID: 22989603
[TBL] [Abstract][Full Text] [Related]
14. Thromboembolic Events While Taking Direct Oral Anticoagulants: An Analysis of Post-market WHO Database Reports from 2012 to 2020.
Mitrovic D; Emmens W; Naimi A; van der Mijle A; Veeger N; van Roon E; van den Bemt P
Clin Drug Investig; 2022 Jul; 42(7):593-598. PubMed ID: 35675030
[TBL] [Abstract][Full Text] [Related]
15. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
16. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
Renda G; di Nicola M; De Caterina R
Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790
[TBL] [Abstract][Full Text] [Related]
17. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
[TBL] [Abstract][Full Text] [Related]
18. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
20. Safety of non-vitamin K antagonist oral anticoagulants - coronary risks.
Caldeira D; Ferreira JJ; Pinto FJ; Costa J
Expert Opin Drug Saf; 2016 Jun; 15(6):731-40. PubMed ID: 26958897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
